A phase 3 study of VX-659 Combination Therapy with Tezacaftor and Ivacaftor in subjects with Cystic Fibrosis in people who have one F508del/Min patients.

Trial Profile

A phase 3 study of VX-659 Combination Therapy with Tezacaftor and Ivacaftor in subjects with Cystic Fibrosis in people who have one F508del/Min patients.

Planning
Phase of Trial: Phase III

Latest Information Update: 03 Feb 2018

At a glance

  • Drugs VX 659 (Primary) ; Ivacaftor/tezacaftor
  • Indications Cystic fibrosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Feb 2018 New trial record
    • 31 Jan 2018 According to a Vertex Pharmaceuticals media release, company is discussing with regulatory authorities to finalise the design of this study. The study is expected to initiate in first half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top